These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 14628497)

  • 1. The effect of androgen supplementation therapy on the prostate.
    Kaufman JM
    Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring androgen replacement therapy: testosterone and prostate safety.
    Morales A
    J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate.
    Scarano WR; Vilamaior PS; Taboga SR
    Anat Rec A Discov Mol Cell Evol Biol; 2006 Nov; 288(11):1190-200. PubMed ID: 17031809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
    Morgunov LIu; Vertkin AL; Pushkar' DIu
    Urologiia; 2007; (5):49-51. PubMed ID: 18254226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone in older men after the Institute of Medicine Report: where do we go from here?
    Harman SM
    Climacteric; 2005 Jun; 8(2):124-35. PubMed ID: 16096168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Testosterone substitution in patients with hypogonadism].
    Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
    Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone replacement therapy and prostate risks: where's the beef?
    Morgentaler A
    Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone and the aging male.
    Tenover JL
    J Androl; 1997; 18(2):103-6. PubMed ID: 9154502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.
    Shigehara K; Sugimoto K; Konaka H; Iijima M; Fukushima M; Maeda Y; Mizokami A; Koh E; Origasa H; Iwamoto T; Namiki M
    Aging Male; 2011 Mar; 14(1):53-8. PubMed ID: 21171937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer in men using testosterone supplementation.
    Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
    J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens and the ageing male.
    Swerdloff RS; Wang C
    Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):349-62. PubMed ID: 15261842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
    Lunenfeld B; Saad F; Hoesl CE
    Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone supplementation: what and how to give.
    Jockenhövel F
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer risk in testosterone-treated men.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
    Morgentaler A
    J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.